Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bederra marks first medical buy with Diagnos' imaging tech

This article was originally published in Clinica

Executive Summary

Equipment leasing company Bederra has acquired diagnostic imaging company Diagnos in exchange for 15 million shares. The deal, which saw Diagnos become a wholly-owned subsidiary of Bederra on December 27 2007, enables the Texas, Houston-based acquirer to offer its customers PET technology designed to detect cancer, Alzheimer's disease, dementia and heart disease. Diagnos' technology currently only has an installed base of 18 units all within the Houston area. The company will hope the Bederra deal opens up new sales routes to more states for the technology. The PET technology is accepted by Medicare and all private insurance carriers. President of Bederra Graham Williams said this acquisition marked the first of many acquisitions in the medical sector that the company had planned in the coming years. According to Bederra, the equipment leasing market generates revenues of around $200bn every year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT045868

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel